• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular pharmaceutics >Comparative Analysis between [F-18]Fludarabine-PET and [F-18]FDG-PET in a Murine Model of Inflammation
【24h】

Comparative Analysis between [F-18]Fludarabine-PET and [F-18]FDG-PET in a Murine Model of Inflammation

机译：[F-18]氟达拉滨-PET和[F-18] FDG-PET在小鼠炎症模型中的比较分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lymphoma research has advanced thanks to introduction of [F-18]fludarabine, a positron-emitting tool. This novel radiotracer has been shown to display a great specificity for lymphoid tissues. However, in a benign process such as inflammation, the uptake of this tracer has not been questioned. Indeed, in inflammatory zones, elevated glucose metabolism rate may result in false-positives with [F-18]FDG-PET Imaging. In the present investigation, it has been argued that cells, involved in inflammation, might be less avid of [F-18]fludarabine. To generate inflammation, Swiss mice were intramuscularly injected with 0.1 mL of turpentine oil into the right front paw. Imaging sessions with F-18-labeled tracers named above were conducted on days 5 and 25 after inoculation. For each animal, volumes of interest (VOI), delineating the muscle of the inflamed (IP) and normal paws (NP), were determined on PET scans. For characterization of inflammation, muscle samples from IP and NP were stained with hematoxylin and eosin (H&E). In early (day 5) inflammation, [F-18]FDG accumulation was 4.00 +/- 1.65 times greater in the IP than in the contralateral NP; for [F-18]fludarabine, this IP/NP ratio was 1.31 +/- 0.28, resulting in a significant difference between radiotracer groups (p < 0.01). In late (day 25) inflammation, the IP/NP ratios were 2.07 +/- 0.49 and 1.03 +/- 0.07, for [F-18]FDG and [F-18]fludarabine, respectively (p < 0.001). [F-18]Fludarabine showed significantly weaker uptake in inflammation when compared with [F-18]FDG. This encouraging finding suggests that [F-18]fludarabine-PET might well be a robust approach for distinguishing tumor from inflammatory tissue, avoiding false-positive PET results and thus enabling an accurate imaging of lymphoma.
机译：由于引入了正电子发射工具[F-18]氟达拉滨，淋巴瘤的研究取得了进展。该新型放射性示踪剂已显示出对淋巴组织的高度特异性。然而，在诸如炎症的良性过程中，对这种示踪剂的摄取没有质疑。的确，在[F-18] FDG-PET成像中，在炎症区，葡萄糖代谢率升高可能会导致假阳性。在目前的研究中，有人认为参与炎症的细胞可能对[F-18]氟达拉滨的热情较低。为了产生炎症，向瑞士小鼠的右前爪肌肉注射0.1 mL松节油。接种后第5天和第25天使用上述F-18标记示踪剂进行成像。对于每只动物，在PET扫描中确定了勾勒出发炎（IP）和正常爪子（NP）肌肉的目标体积（VOI）。为了表征炎症，用苏木精和曙红（H＆E）对IP和NP的肌肉样品进行染色。在早期炎症（第5天）中，IP中[F-18] FDG的积累是对侧NP的4.00 +/- 1.65倍;对于[F-18]氟达拉滨，该IP / NP比为1.31 +/- 0.28，导致放射性示踪剂组之间存在显着差异（p <0.01）。在发炎后期（第25天），[F-18] FDG和[F-18]氟达拉滨的IP / NP比分别为2.07 +/- 0.49和1.03 +/- 0.07（p <0.001）。与[F-18] FDG相比，[F-18]氟达拉滨对炎症的吸收明显弱。这一令人鼓舞的发现表明，[F-18]氟达拉滨-PET可能是区分肿瘤与炎性组织，避免假阳性PET结果，从而使淋巴瘤准确成像的可靠方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号